Search This Blog

Tuesday, April 23, 2019

Anti-Vaxxer Movement Cites Distrust of Pharma Industry as Reason to Skip Shots

Over the past few years, there seems to be a growing number of people in the United States who, for a myriad of reasons, opt out of vaccinating their children against common pathogens that often have deadly effects – like the measles.
A core reason that some anti-vaxxers, as they’ve become known, have given for refusing to support vaccine use in their lives is a deep distrust of the pharmaceutical industry. This morning, USA Today reported that a significant number of the anti-vaccination proponents claim that there are dangerous side effects to vaccines and the government is shielding the drugmakers from liability due to the National Vaccine Injury Compensation Program. The federal program requires that anyone who claims a vaccine has caused any kind of injury must file a claim through this program.
One of those who distrusts the industry is the head of an advocacy group in the state of Washington, one of the more popular areas for anti-vaxxers. Bernadette Pajer said drug companies have a “pretty poor record over all” in the areas of safety and transparency USA Todayreported.

Since 2001, the percentage of children in the United States who do not receive any vaccines has quadrupled. According to the U.S. Centers for Disease Control and Prevention, said about 1.3 percent of children who were born in 2015 do not receive vaccinations. That number grew from .3 percent in 2001.
A survey released earlier this month indicates that there is a high level of skepticism and distrust for the pharmaceutical industry. The survey, conducted by PatientView, the majority of people tend to hold a negative or indifferent view of the pharmaceutical industry’s reputation. The results show that 41 percent of people surveyed said that the pharma industry has an “Excellent” or “Good” corporate reputation. When it comes to developing beneficial medications, the number of positive responses jumped a bit. The survey showed that 53 percent believed the industry was Excellent” or “Good” at making high-quality products. Although, that was lower than the 57 percent the industry scored in 2017.
Pajer became concerned about vaccine side effects after her son developed severe allergies to food ingredients in the vaccines, USA Today said.
In particular, Pajer pointed to Merck and its vaccine for measles, mumps and rubella. Pajer raised concern due to the company’s ongoing legal battle with a whistleblower who alleges in court that the company has overstated the efficacy of the vaccines. Also, Pajer claims that there is a risk the rubella portion of the vaccine can cause arthritis and that Merck is withholding data showing that risk. The lawsuit, filed in 2010 by two former Merck virologists, claims that Merck faked the efficacy of the vaccine, which was initially approved in the early 1970s.
As the anti-vaccination movement grows, so too do the number of cases of previously controlled illnesses such as the measles. This year there have been 626 confirmed cases of the measles, according to the CDC. The disease had been considered almost eradicated nearly 20 years ago. Outbreaks of the measles have surged across multiple communities in the U.S., including New York, where the outbreak has been severe. Earlier this month, New York City officials issued a mandate requiring that residents in parts of Brooklyn receive MMR vaccinations or face a fine of $1,000. Receiving both recommended doses of the MMR vaccine results in a 97 percent effectiveness in preventing the measles, the CDC said.

Tonix Pharmaceuticals says USAMMDA exercising right to terminate CRADA

Tonix Pharmaceuticals announced that on April 18 the company received a notice of termination, effective April 29, whereby the U.S. Army Medical Materiel Development Activity, or USAMMDA, is exercising its contractual right to terminate without cause the Collaborative Research and Development Agreement, or CRADA, entered into on December 4, 2015 between the company and USAMMDA relating to the development of Tonmya or TNX-102 SL for the treatment of Posttraumatic Stress Disorder. “The termination does not affect Tonix’s finances or the conduct of the ongoing RECOVERY trial in PTSD. Due to the statutory limitations on all CRADAs, Tonix’s agreement with USAMMDA never contemplated nor contained any provision for funding Tonix or any PTSD study. There is, therefore, no financial impact to Tonix as a result of this action. A key objective of the CRADA was for USAMMDA to assist Tonix in recruiting active duty personnel from military treatment facilities into the Phase 2 AtEase and Phase 3 HONOR studies of military-related PTSD. However, no patients were recruited by USAMMDA from MTFs into either study. The ongoing RECOVERY trial is recruiting only patients whose PTSD results from trauma that occurred less than nine years before screening. Since the large U.S. troop deployments into the war zones in Iraq and Afghanistan were more than nine years ago, the number of relevant potential trial participants in MTFs would be lower than during our previous clinical trials. Therefore, we believe there is no patient recruitment impact to Tonix as a result of this action. Although a potential benefit of the CRADA was cooperation in planning PTSD studies, USAMMDA was not involved in the planning or execution of any Tonix PTSD study. Therefore, we believe there is no research or development impact to Tonix as a result of this action,” the company said.
https://thefly.com/landingPageNews.php?id=2895965

Quest Diagnostics backs FY19 adj. EPS view of greater than $6.40 

Consensus $6.45. Backs FY19 revenue guidance of $7.6B-$7.75B, consensus $7.68B.

Zosano Pharma initiated at Cantor Fitzgerald

Cantor starts Zosano Pharma with Overweight rating, $12 price target. Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Zosano Pharma with an Overweight rating and $12 price target. The company’s proprietary delivery platform facilitates rapid transcutaneous absorption of drug candidates and is applicable to multiple therapeutic areas, including migraine and other acute symptom settings, and is appropriate for several classes of drugs, Duncan tells investors in a research note. Zosano is on track to file its first new drug application by the end of 2019 with Qtrypta, a drug that has demonstrated “impressive” Phase 3 clinical data, adds the analyst.

Cantor sees ‘significant’ synergies from Tivity’s acquisition of Nutrisystem

Cantor Fitzgerald analyst Steven Halper says his review of the nutrition/weight management industry supports his view that Tivity Health’s acquisition of Nutrisystem “should be able to generate significant revenue synergies.” The weight management market opportunity is large and continues to expand given attractive industry and policy tailwinds, Halper tells investors in a research note. While the market is competitive, Nutrisystem is well positioned, contends the analyst. He reiterates an Overweight rating on Tivity Health with a $40 price target.

Orthofix announces first U.S. patient implants of M6-C artificial cervical disc

Orthofix Medical announced the first commercial implants of patients with the M6-C artificial cervical disc. The Center for Disc Replacement at Texas Back Institute in Dallas, Texas recently implanted four patients suffering from single level cervical disc degeneration with the newly approved M6-C disc — a next-generation artificial disc developed to replace an intervertebral disc damaged by cervical disc degeneration. Designed with an artificial viscoelastic nucleus and fiber annulus that mimics the anatomic structure of a natural disc, the M6-C device is the only artificial cervical disc available in the U.S. that enables compression or “shock absorption” at the implanted level. The disc also provides a controlled range of motion when the spine transitions in its combined complex movements.

Intuitive Surgical price target lowered to $611 from $684 at Citi

Citi analyst Amit Hazan lowered his price target for Intuitive Surgical to $611 from $684 following last week’s “surprise miss” but keeps a Buy rating on the shares. The analyst sees “very solid leading indicators that offer encouragement for longer term fundamentals.” He also believes the recent weakness in the shares present a “compelling buying opportunity.”